We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
bluebird bio Inc | NASDAQ:BLUE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0427 | 4.81% | 0.9298 | 0.9101 | 0.928 | 0.948 | 0.87 | 0.8946 | 8,633,205 | 00:59:51 |
By Colin Kellaher
Bristol Myers Squibb Co. and bluebird bio Inc. said the U.S. Food and Drug Administration approved Abecma for the treatment of adults with the blood cancer multiple myeloma.
The companies said the approval covers the CAR T cell immunotherapy formerly known as idecabtagene vicleucel, or ide-cel, for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
New York-based Bristol Myers and bluebird, a Cambridge, Mass., biotechnology company, are jointly developing and commercializing Abecma in the U.S. For bluebird, the FDA nod marks its first approved treatment in oncology and first approved treatment in the U.S.
Shares of bluebird, which closed Friday at $29.98, rose more than 9% in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 29, 2021 07:38 ET (11:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year bluebird bio Chart |
1 Month bluebird bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions